Identifying Genetic Factors of Brugada Syndrome in Thai and Southeast Asian Populations
Led by Chulalongkorn University · Updated on 2026-10-30
750
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Brugada syndrome BrS is a major cause of sudden death in young Asian adults, including those in Thailand. This observational study aims to explore the link between genetic changes and both the diagnosis and severity of BrS. Researchers are recruiting Thai patients diagnosed with BrS confirmed by a specific ECG pattern, along with healthy volunteers, to better understand the conditions genetic basis.
Participants include Thai individuals with confirmed Brugada type 1 ECG and healthy controls without Brugada ECG markers. Data gathered includes demographic and clinical details, ECG results, and blood samples for genetic testing using whole genome sequencing and SNP arrays. Patients with BrS are followed over time to monitor symptoms and device shocks, while the study analyzes how genetic differences relate to clinical severity.
During the study, participants provide clinical information and undergo ECG and blood sample collection. BrS patients are prospectively monitored for arrhythmic events and device activity. Researchers will measure the relationship between genetic variants and BrS phenotype over seven years, as well as the natural history and epidemiology of BrS. The study is sponsored by Chulalongkorn University and includes long-term follow-up until 2031.
CONDITIONS
Brief Title
Southeast Asian Brugada Syndrome Cohort
Research Team
A
Apichai Khongphatthanayothin, MD
P
Pharawee Wandee, BSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Confirmed diagnosis of Brugada syndrome with type 1 ECG in right precordial leads (v1 or v2), with or without pharmacologic provocative testing
ECG confirmation by standard 12-lead ECG or Brugada lead
You will not qualify if you...
Presence of other heart diseases such as ischemic heart disease, valvular heart disease, congenital heart disease, myocarditis, or pericarditis
Only type 2 or type 3 Brugada ECG without type 1 ECG during provocative testing or Brugada lead
One-time type 1 Brugada ECG recorded during drug use without reproducibility
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Monitoring
Duration - Up to 7 years
Participants provide clinical data, ECG recordings, and blood samples for genetic studies. Brugada syndrome patients are followed over time to observe symptoms and device activity.
Periodic visits as scheduled
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Study of Catheter Ablation Using High-Density Mapping for Treating Brugada Syndrome Patients with ECG Type 1 and 2 Patterns
Long-Term Follow-Up Study on Outcomes and Recurrence Risk After Treatment of Cardiac Arrhythmias at University Heart Center Hamburg
Studying Protein Distribution in Cheek Cell Samples to Diagnose Heritable Arrhythmic Heart Disorders and Identify Family Members at Risk
Monitoring Heart Electrical Activity in High-Risk Pregnancies to Detect Risks of Fetal Death Using Fetal Magnetocardiography and Neonatal ECG
Building a National Registry for Hereditary Cardiovascular Diseases in Brazil to Improve Patient Care Using Genetic Testing
Identifying Genetic Factors of Brugada Syndrome in Thai and Southeast Asian Populations
UZ Brussel Heart Rhythm Management Center Registry for Patients with Brugada Syndrome
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013.